A Randomized Trial of PHOTOdynamic Surgery in Non-Muscle-Invasive Bladder Cancer

NEJM Evid. 2022 Oct;1(10):EVIDoa2200092. doi: 10.1056/EVIDoa2200092. Epub 2022 Sep 2.

Abstract

PDD or WL Resection of Tumors in NMIBCIn this open-label trial, patients with intermediate- or high-risk non-muscle-invasive bladder cancer at diagnosis were randomly assigned to photodynamic diagnosis or white light-guided transurethral resection of bladder tumor. Three-year recurrence-free rates were 57.8% and 61.6% in the PDD and WL groups, respectively, with no difference in quality-adjusted life years between the treatment groups at 3 years.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aminolevulinic Acid
  • Humans
  • Non-Muscle Invasive Bladder Neoplasms*
  • Photosensitizing Agents
  • Urinary Bladder Neoplasms* / diagnosis
  • Urologic Surgical Procedures

Substances

  • Photosensitizing Agents
  • Aminolevulinic Acid